Syndax Pharmaceuticals, Inc. (SNDX) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Syndax Pharmaceuticals, Inc. (SNDX) closed at USD 13.53 on 2026-10-14, a change of +0.1 % over the past year, with a market capitalization of USD 1.21B.

Syndax Pharmaceuticals, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Syndax Pharmaceuticals, Inc. key figures

Previous close

USD 13.53 (2026-10-14)

1-year change

+0.1 %

Market cap

USD 1.21B

Enterprise value

USD 1.25B

P/E ratio (trailing)

-5.59

P/E ratio (forward)

-16.27

EPS (trailing)

-2.44

EPS (forward)

-0.84

PEG ratio

n/a

Price to book

80.77

Revenue growth

91.8 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

10.06

Employees

298

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Syndax Pharmaceuticals, Inc. and compare it with other stocks.